Trial Profile
Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke (ESS)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Johnson & Johnson; Parexel International
- 17 May 2014 New trial record